Key Highlights

  • Third-quarter Revenue was USD 54.5 million, against USD 104.3 million a year earlier.
  • DefenCath net sales were USD 17.2 million in the quarter.
  • Cash, cash equivalents and short-term investments were USD 355.2 million.
  • A definitive agreement was announced to acquire substantially all Heron assets.

CorMedix (NASDAQ:CRMD) reported third-quarter 2026 consolidated revenue of USD 54.5 million, against USD 104.3 million in the third quarter of 2025 and an estimate of USD 51.76 million. Loss per share was USD 0.19, against an estimate of USD 0.12. Revenue for the nine months was USD 283.9 million, against USD 183.1 million, an increase of USD 100.8 million, or 55%.

Third-quarter revenue consisted of USD 17.2 million in DefenCath net sales and USD 37.3 million from the rest of the portfolio. The rest of the portfolio comprised USD 31.4 million of product sales and approximately USD 5.9 million of contract revenue and grant income under its BARDA agreement.

DefenCath Pricing and Revenue Adjustments

Management said the year-over-year decline in DefenCath revenue primarily reflects lower net pricing tied to the July 1 transition to the post-TDAPA reimbursement period. It said large outpatient dialysis customers largely maintained utilization during the quarter despite the reimbursement change. DefenCath net revenue included a USD 5 million favorable change in estimate related to certain Medicaid rebate and product return allowances, reflecting updated information on Medicaid utilization and product return experience, both of which have been much lower than previously estimated.

Operating Expenses

Total operating expenses were USD 36.6 million in the third quarter, against USD 41.7 million, a decrease of approximately 12%. Management said the reduction mainly reflects merger-related and reorganization costs following the Melinta Acquisition in the prior-year period, partly offset by a full quarter of costs for the expanded organization against one month of Melinta's costs in the prior-year quarter.

Research and development expenses were USD 7.0 million, up USD 1.9 million, or 38%, from USD 5.1 million, which management attributed to higher personnel and clinical trial costs. Selling and Marketing expenses were USD 11.7 million, up USD 0.5 million, or 4%, from USD 11.2 million. General and administrative expenses were USD 17.9 million, down USD 7.6 million, or 30%, from USD 25.5 million.

Amortization of intangible Assets was USD 10.3 million, against USD 3.6 million. For the nine months, cost of sales was USD 40.7 million, against USD 10.9 million, and intangible asset amortization was USD 30.9 million, against USD 3.7 million. Research and Development expenses for the nine months were USD 20.9 million, against USD 10.7 million, and general and administrative expenses were USD 54.7 million, against USD 44.6 million.

Heron Therapeutics Acquisition and Liquidity

Earlier in the week of the call, the company announced a definitive agreement to acquire substantially all of the assets of Heron Therapeutics, including commercial and pipeline assets. The transaction remains subject to approval by Heron's stockholders, regulatory clearance and other customary closing conditions. Management described four pillars of strategic rationale, the first being scale and Diversification across acute care and hematology-oncology supportive care.

Management said Heron's portfolio generated approximately USD 150 million of net product revenue over the trailing 12 months. It guides the acquired products to contribute approximately USD 125 million to USD 150 million of revenue on a pro forma 2027 basis, which it said roughly doubles the revenue base for the non-DefenCath portfolio. It said the second pillar is commercial and operational Leverage across institutional settings of care.

As of September 30, 2026, the company had cash, cash equivalents and short-term investments of USD 355.2 million, excluding restricted cash of USD 1.0 million, against USD 148.5 million at December 31, 2025, also excluding USD 1.0 million of restricted cash.

The reported items for the quarter are revenue of USD 54.5 million, DefenCath net sales of USD 17.2 million, operating expenses of USD 36.6 million, cash and investments of USD 355.2 million and the Heron agreement. The company is listed on the Nasdaq Global Market.